anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The introductory session, emphasizing real-world experiences, will involve a brief training session followed by simulated navigation experiences in a convenient location to the users. Participants will use V-NAV to record approximately 8 locations, then will be given instructions to find these locations again. The V-NAV prototype's logging software will measure distance walked and task time. Participants will complete a study-specific tool covering the relevant attributes of the V-NAV prototype, as well as a standardized tool, the NASA TLX (Task Load Index).

Subsequently, participants will complete a take-home trial, during which they will be encouraged to use the V-NAV features regularly to support their everyday community navigation activities. Participants will be contacted approximately weekly with a "check-in" to answer questions and resolve any emergent technical problems. At the conclusion of the trial, a product-specific tool and an appropriate standardized tool, the PIADS (Psychosocial Impact of Assistive Devices Scale) will be administered.
The present invention is based, at least in part, on the discovery of certain genes which are absent from T regulatory cells and present on effector T cells (Th1 and Th2), e.g., Protein Kinase C Theta (PKC theta). Furthermore, a pathway essential for the production of inflammatory cytokines and cellular proliferation of inflammatory, effector T cells is not utilized by regulatory T cells. Accordingly, in one aspect the invention provides. methods for promoting regulatory T cell function in immune cells relative to effector T cell function, comprising contacting immune cells with an agent that inhibits a protein kinase C theta pathway in the immune cells. In another aspect, the invention provides methods for treating a subject having a condition that would benefit from promoting regulatory T cell function relative to effector T cell function in the subject, comprising administering an agent that inhibits a protein kinase C theta pathway in immune cells of the subject. In still another aspect, the invention provides assays for screening compounds that specifically modulate a effector T cell function without modulating regulatory T cell function comprising contacting a protein kinase C theta pathway molecule with a test compound and determining the ability of the test compound to modulate the protein kinase C theta pathway molecule activity, wherein modulation of a protein kinase C theta pathway molecule activity indicates that the test compound is a specific modulator of a effector T cell function.
All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
FIELD: medicine, immunotherapy. SUBSTANCE: invention relates to vaccine showing effectiveness for inhibition of cerebrospinal sclerosis, method for inducing immune response. Invention involves vaccine containing attenuated T-cells grown in the presence of myelin proteins, in part, in the presence of bovine proteins. In preferable variant of invention vaccine comprises attenuated T-cells prepared by culturing autological circulating mononuclear cells in the presence of bovine total myelin proteins by selection and multiplication of T-cells with immune response for myelin proteins and attenuation of cells by irradiation. The advantage of invention involves the development of effective nontoxic agent for treatment of patients with primary or secondary cerebrospinal sclerosis. EFFECT: valuable medicinal properties of vaccine. 18 cl, 14 dwg, 1 ex
Despite decades of effort aimed at developing clinically effective cell therapies, including mixed population mononuclear cells, to revascularize the ischemic limb, there remains a paucity of patient-based studies that inform the function and fate of candidate cell types. In this study, we showed that circulating proangiogenic/arteriogenic monocytes (PAMs) expressing the FcγIIIA receptor CD16 were elevated in patients with chronic limb-threatening ischemia (CLTI), and these amounts decreased after revascularization. Unlike CD16-negative monocytes, PAMs showed large vessel remodeling properties in vitro when cultured with endothelial cells and smooth muscle cells and promoted salvage of the ischemic limb in vivo in a mouse model of hindlimb ischemia. PAMs showed a propensity to migrate toward and bind to ischemic muscle and to secrete angiogenic/arteriogenic factors, vascular endothelial growth factor A (VEGF-A) and heparin-binding epidermal growth factor. We instigated a first-in-human single-arm cohort study in which autologous PAMs were injected into the ischemic limbs of five patients with CLTI. Greater than 25% of injected cells were retained in the leg for at least 72 hours, of which greater than 80% were viable, with evidence of enhanced large vessel remodeling in the injected muscle area. In summary, we identified up-regulation of a circulatory PAM subpopulation as an endogenous response to limb ischemia in CLTI and tested a potentially clinically relevant therapeutic strategy.
BACKGROUND: Women with polycystic ovary syndrome (PCOS) have increased odds of concurrent depression, indicating that the relationship between PCOS and depression is more likely to be comorbid. However, the underlying mechanism remains unclear. Here, we aimed to use bioinformatic analysis to screen for the genetic elements shared between PCOS and depression.
METHODS: Differentially expressed genes (DEGs) were screened out through GEO2R using the PCOS and depression datasets in NCBI. Protein-protein interaction (PPI) network analysis and enrichment analysis were performed to identify the potential hub genes. After verification using other PCOS and depression datasets, the associations between key gene polymorphism and comorbidity were further studied using data from the UK biobank (UKB) database.
RESULTS: In this study, three key genes, namely, SNAP23, VTI1A, and PRKAR1A, and their related SNARE interactions in the vesicular transport pathway were identified in the comorbidity of PCOS and depression. The rs112568544 at SNAP23, rs11077579 and rs4458066 at PRKAR1A, and rs10885349 at VTI1A might be the genetic basis of this comorbidity.
CONCLUSIONS: Our study suggests that the SNAP23, PRKAR1A, and VTI1A genes can directly or indirectly participate in the imbalanced assembly of SNAREs in the pathogenesis of the comorbidity of PCOS and depression. These findings may provide new strategies in diagnosis and therapy for this comorbidity.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutical industry, in particular to composition for prevention and treatment of cancer. Pharmaceutical composition for prevention and treatment of cancer, which contains one or more components selected from group, consisting of cell line obtained from Taxus cambium or procambium with specified characteristics. Functional food product for prevention or improvement of state in case of cancer, which contains one or more components selected from group, consisting of cell line obtained from Taxus cambium or procambium with specified characteristics. ^ EFFECT: composition and product efficiently induce death of cancer cells, have minimal side effects. ^ 11 cl, 22 dwg, 4 tbl, 8 ex
PURPOSE:To obtain the microcapsuled magnetic superfine particles excellent in resistance to corrosion and environment and the magnetic immobilized enzyme and magnetic immobilized formulation using the superfine particles by providing a core material made of an organic polymer in which magnetic superfine particles are dispersed and a clad material made of an org. polymer having a functional group on its surface. CONSTITUTION:The microcapsuled magnetic superfine particle consists of the core material made of an org. polymer in which magnetic superfine particles are dispersed and the clad material made of an org. polymer having a functional group on its surface. The superfine particle is excellent in resistance to corrosion and environment. An enzyme is bonded to the functional group. As a result, a magnetic immobilized enzyme capable of being selectively separated and recovered by the external magnetic field and having a high reaction yield is obtained. The magnetic immobilized formulation obtained by incorporating an org. polymer layer in which a medical material is dispersed into the clad material is appropriately used as the carrier for a medical material excellent in resistance to corrosion and environment.
Cholestasis is the predominate feature of many pediatric hepatobiliary diseases. The physiologic flow of bile requires multiple complex processes working in concert. Bile acid (BA) synthesis and excretion, the formation and flow of bile, and the enterohepatic reuptake of BAs all function to maintain the circulation of BAs, a key molecule in lipid digestion, metabolic and cellular signaling, and, as discussed in the review, a crucial mediator in the pathogenesis of cholestasis. Disruption of one or several of these steps can result in the accumulation of toxic BAs in bile ducts and hepatocytes leading to inflammation, fibrosis, and, over time, biliary and hepatic cirrhosis. Biliary atresia, progressive familial intrahepatic cholestasis, primary sclerosing cholangitis, and Alagille syndrome are four of the most common pediatric cholestatic conditions. Through understanding the commonalities and differences in these diseases, the important cellular mechanistic underpinnings of cholestasis can be greater appreciated.
The invention provides isolated nucleic acids encoding transmembrane transport proteins and fragments, derivatives, and variants thereof. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides, and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes relating to transmembrane transport of charged organic compounds such as prostaglandins and thromboxanes.
After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley "blindly" by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
FIELD: medicine. SUBSTANCE: method involves separating mucoperiosteal flap, its deepithelialization, removing granulations and subgingival deposits, applying antiseptic treatment of wound surfaces, treating osteoplastic material with fibroplastic material, implanting osteoplastic material into bone defects. Human embryo lung diploid cell suspension is used as fibroplastic material. The cells are cultured on osteoplastic material in growth medium with 10% fetal blood serum taken from cattle at a dose of 60000- 80000 cells/ml of growth medium. Hapcol or Collapan are used as osteoplastic material. EFFECT: enhanced effectiveness of therapeutic efficiency; excluded adverse side effects. 5 cl
Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial.
Participants will be asked to sit in front of a table of appropriate height with their arms resting on the table and a mirror (35 cm × 35 cm) placed between the patient's arms. The non-affected arm will be placed in front of the mirror and the affected arm will be placed and obscured. Patient will engage in specific exercises or movements using the affected limb while observing the mirror reflection. The movements will consist of forearm rotation, elbow, wrist, and finger flexion and extension movements, and hand grasping. Appropriate movement tasks will be selected according to the function of the affected upper limb. This exercise will be performed 45 minutes per day, 3 times per week for 6 weeks.
Antiretroviral therapy (ART) has reduced the mortality and morbidity associated with HIV. However, irrespective of treatment, people living with HIV remain at a higher risk of developing non-AIDS-associated diseases. In 2019, the World Health Organization recommended the transition from efavirenz (EFV)- to dolutegravir (DTG)-based ART. Data on the impact of this transition are still limited. The current study therefore investigated the metabolic profiles, cytokine inflammatory responses, and platelet activation before and after the treatment transition. Plasma samples from nine virally suppressed adults living with HIV and sixteen healthy, HIV-uninfected individuals residing in Gauteng, South Africa were compared. Metabolite and cytokine profiles, and markers associated with platelet activation, were investigated with untargeted proton magnetic resonance metabolomics, multiplex suspension bead array immunoassays, and sandwich enzyme-linked immunosorbent assays, respectively. In those individuals with normal C-reactive protein levels, the transition to a DTG-based ART regimen resulted in decreased concentrations of acetoacetic acid, creatinine, adenosine monophosphate, 1,7-dimethylxanthine, glycolic acid, 3-hydroxybutyric acid, urea, and lysine. Moreover, increased levels of formic acid, glucose, lactic acid, myo-inositol, valine, glycolic acid, and 3-hydroxybutyric acid were observed. Notably, levels of interleukin-6, platelet-derived growth factor-BB, granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, soluble cluster of differentiation 40 ligand, as well as regulated on activation, normal T-cell expressed and secreted (RANTES) reached levels close to those observed in the healthy control participants. The elevated concentration of macrophage inflammatory protein-1 alpha was the only marker indicative of elevated levels of inflammation associated with DTG-based treatment. The transition from EFV- to DTG-based regimens therefore appears to be of potential benefit with metabolic and inflammatory markers, as well as those associated with cardiovascular disease and other chronic non-AIDS-related diseases, reaching levels similar to those observed in individuals not living with HIV.
PROBLEM TO BE SOLVED: To obtain a hair cosmetic having a high hair setting effect and being capable of highly maintaining the hair set firm at a high humidity by blending a specific non-aqueous polymer dispersion. SOLUTION: This hair cosmetic is blended with a non-aqueous polymer dispersion obtained by dispersing a polymer in an organic solvent. As the organic solvent, one or more than two kind(s) of volatile silicone expressed by formula I ((m) is 0 to 5) or formula II ((n) is 3 to 7) is preferable. As the polymer, acrylic ester, methacrylic ester, vinyl group-containing silicone or vinylidene group-containing silicone, etc., is preferable. The non-aqueous polymer dispersion is obtained by radical polymerization of a radical polymerizable monomer in an organic solvent using a radical polymerization initiator. The blending amount of the non-aqueous polymer dispersion is 0.1 to 70wt.%.
The purpose of this pilot study is to determine if patients randomized to a hospital sleep environment intervention would have improved sleep quality and reduced fatigue as compared to the patients not receiving the intervention (standard care).

All patients enrolled on SJMB03 and admitted to receive either the 2nd or 3rd course of chemotherapy will be eligible for the study. The patients are admitted for four to six days and all participants will wear an actigraph to collect information on 8 sleep quality indicators for each of the six days. In addition, fatigue measurements will also be collected and compared between the two groups. Given the nature of the intervention, it is difficult to follow the traditional randomization scheme and randomize eligible patients to the intervention or standard care because there is a high likelihood of design contamination secondary to interactions among family members and among the nurses in regards to the different care for the study participants in the two study groups. Therefore, this study will use a group randomized trial design with patients randomized by month. That is, all patients admitted in a month randomized to be an intervention month will receive the intervention and all patients admitted to a standard care month will not receive the intervention. This type of randomization plan has notable strengths that match this study design but it also has two potential challenges: 1) patients randomized within the last five days of each month will continue to receive the assigned treatment to which they were randomized although this treatment assignment will continue into a different month that could have been randomized to the same or different condition as the previous month, and 2) with random assignments of months to the two treatment arms, there is a possibility of an unequal distribution of patients randomized to the two groups.
This study aims to evaluate the effect and underlying mechanism of ferulic acid (FA) in alleviating the acute liver injury by ionizing radiation (IR) in vivo. Rats were divided into 4groups (Groups: control, 6Gy irradiated (IRR), FA (50 mg/kg) and FA + IRR). The results showed that FA can effectively inhibit liver damage and restore the structure and function of the liver. In mechanism, FA prevented IR-induced liver fibrosis and blocked the JAK/STAT signaling pathway to effectively inhibit the hepatic inflammatory response; and inhibited IR-induced oxidative stress (OS) by upregulating the Nrf2 signaling pathway and promoting the synthesis of several antioxidants. Moreover, FA inhibited ferroptosis in the liver by stimulating the expression of GPX4 and SLC7A11. FA reduced lipid peroxidation by downregulation of the reactive oxygen species (ROS) production and iron aggregation, thus inhibiting ferroptosis and alleviating IR-induced liver injury. In conclusion, the current study suggests the potential complex mechanisms underlying the mitigating impact of FA in IR-induced ferroptotic liver damage.
Patients in the Vitamins C and B1 arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
The current gold standard to treat large cartilage defects is autologous chondrocyte transplantation (ACT). As a new surgical method of cartilage regeneration, minced cartilage implantation (MCI) is increasingly coming into focus. The aim of this study is to investigate the influence of chondrogenesis between isolated and cultured chondrocytes compared to cartilage chips in a standardized inflammation model with the proinflammatory cytokine TNFα. Articular chondrocytes from bovine cartilage were cultured according to the ACT method to passage 3 and transferred to spheroid culture. At the same time, cartilage was fragmented (<1 mm3) to produce cartilage chips. TNFα (20 ng/mL) was supplemented to simulate an inflammatory process. TNFα had a stronger influence on the passaged chondrocytes compared to the non-passaged ones, affecting gene expression profiles differently between isolated chondrocytes and cartilage chips. MCI showed less susceptibility to TNFα, with reduced IL-6 release and less impact on inflammation markers. Biochemical and histological analyses supported these findings, showing a greater negative influence of TNFα on the passaged pellet cultures compared to the unpassaged cells and MCI constructs. This study demonstrated the negative influence of TNFα on chondrogenesis in a chondrocyte spheroid culture and cartilage fragment model. Passaged chondrocytes are more sensitive to cytokine influences compared to non-passaged cells and chondrons. This suggests that MCI may have superior regeneration potential in osteoarthritic conditions compared to ACT. Further investigations are necessary for the translation of these findings into clinical practice.
PURPOSE:To activate pituitary adrenocortical hormone, to safely and collectively activate a human body and to effect the restoration of health or remedy of diseases, by using NEO-OHTAKA(R) (a food composed mainly of Na, K and carbohydrate, etc.). CONSTITUTION:Pituitary adrenocortical hormone can be activated by drinking NEO-OHTAKA for 3-7 days while restricting the taking of food inhibiting the drug action of NEO-OHTAKA. A human body is activated thereby to effect the restoration of health and the stimulation of the curing power of the body against diseases. NEO-OHTAKA is composed of nutrients to prevent the lowering of physical strength, electrolytes having drug action and substances assisting the drug action. The activation of pituitary adrenocortical hormone by NEO- OHTAKA is started by the resorption and excretion action of nephrorenal tubule caused by a low-Na and high-K component of NEO-OHTAKA. NEO- OHTAKA can be produced by extracting an animal or vegetable or a substance produced by fermenting an animal or vegetable.